CN113476520A - Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application - Google Patents

Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application Download PDF

Info

Publication number
CN113476520A
CN113476520A CN202110888781.2A CN202110888781A CN113476520A CN 113476520 A CN113476520 A CN 113476520A CN 202110888781 A CN202110888781 A CN 202110888781A CN 113476520 A CN113476520 A CN 113476520A
Authority
CN
China
Prior art keywords
extract
compound
preparation
preparation process
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110888781.2A
Other languages
Chinese (zh)
Inventor
许庆友
马河
徐凤霞
秦承雪
王璐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANDONG HANFANG PHARMACEUTICAL CO Ltd
Original Assignee
SHANDONG HANFANG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANDONG HANFANG PHARMACEUTICAL CO Ltd filed Critical SHANDONG HANFANG PHARMACEUTICAL CO Ltd
Priority to CN202110888781.2A priority Critical patent/CN113476520A/en
Publication of CN113476520A publication Critical patent/CN113476520A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/648—Myriapods, e.g. centipedes or millipedes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of medicines, and particularly relates to a preparation process of a compound phellodendron extract, a compound phellodendron extract preparation and antiallergic application. The preparation method of the compound cortex Phellodendri extract comprises pulverizing cortex Phellodendri into coarse powder; mixing with other raw materials; adding water containing solubilizer, decocting, filtering, concentrating the filtrate to obtain fluid extract, and extracting with ethanol. The preparation process of the compound phellodendron extract ensures the quality of the prepared extract product by adding the special complex solubilizer in the decocting process, does not layer or precipitate in the preparation process, and can improve the transfer rate of effective components, and the obtained extract has beneficial application value in the aspect of antianaphylaxis.

Description

Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a preparation process of a compound phellodendron extract, a compound phellodendron extract preparation and antiallergic application.
Background
The compound phellodendron liquid liniment mainly comprises phellodendron, fructus forsythiae, honeysuckle, dandelion and centipede, has strict formula, monarch, minister, assistant and guide, combines the medicines, has precise and appropriate compatibility, and has the effects of clearing away heat and toxic materials, resisting bacteria and diminishing inflammation, and reducing swelling and removing putrefaction. Research has shown that berberine hydrochloride is used as an important index for controlling the quality of the compound phellodendron bark liquid liniment and is one of the effective components of the compound phellodendron bark liquid with the functions of resisting inflammation, promoting healing and the like. Berberine hydrochloride, as one of the alkaloid components from phellodendron amurense, has the characteristic of being insoluble in water and has poor bioavailability. The compound phellodendron amurense liquid liniment is prepared by a water extraction and alcohol precipitation method, and the transfer rate of the content of berberine hydrochloride serving as an effective component of the phellodendron amurense liquid liniment is relatively low, and the loss is serious.
The solubilizer is a surfactant that serves a solubilizing effect. The surfactant can increase the solubility of the insoluble drug because the surfactant and the insoluble drug form a transparent micelle after reaching the critical micelle concentration, the insoluble drug is wrapped inside the micelle, and the surfactant shell is arranged outside the micelle. However, most surfactant solutions are easy to cause solubility reduction when heated, and further cause turbidity and even delamination, which leads to solubilization reduction and brings trouble for subsequent preparation forming, so that, in general, the solubilizer is often used in the preparation forming stage, and is rarely added directly during extraction.
Disclosure of Invention
The invention provides a preparation process of a compound phellodendron extract, a compound phellodendron extract preparation and antiallergic application.
One of the technical schemes adopted by the invention is as follows:
a preparation process of a compound phellodendron extract comprises the following raw materials in parts by weight: 20-120 parts of fructus forsythiae, 20-60 parts of golden cypress, 20-60 parts of honeysuckle, 20-60 parts of dandelion and 1-5 parts of centipede; the extraction preparation method comprises the following operation steps:
taking the phellodendron amurense in parts by weight, and crushing the phellodendron amurense into coarse powder; mixing with other raw materials; adding water containing solubilizer, decocting, filtering, concentrating the filtrate to obtain fluid extract, and extracting with ethanol;
the solubilizer is a compound composition of tween 80, span 40 or polyoxyethylene hydrogenated castor oil and poloxamer;
the content of berberine hydrochloride in the prepared compound cortex Phellodendri extract is not less than 1.0% of dry product.
Further, the solubilizer is a compound composition of tween 80 and poloxamer; the solubilizer accounts for 0.55 to 1.1 percent of the water for decoction; wherein the dosage ratio of the Tween 80 to the poloxamer is 10: 1.
Further, the solubilizer is a compound composition of span 40 and poloxamer, and accounts for 0.55-1.1% of the water used for decoction; wherein the dosage ratio of span 40 to poloxamer is 10: 1.
Further, the compound composition of polyoxyethylene hydrogenated castor oil and poloxamer, wherein the solubilizer accounts for 0.1-0.2% of the water for decoction; wherein the dosage ratio of the polyoxyethylene hydrogenated castor oil to the poloxamer is 1: 1.
Further, the decocting operation comprises: decocting for 3 times, 1 hr for the first time, 45 min for the second time, and 30 min for the third time, and mixing decoctions.
Further concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15 at 50 deg.C; the alcohol extraction comprises adding ethanol to make the alcohol content reach 70%, standing for 24 hr, filtering, and concentrating under reduced pressure until no alcohol smell is produced.
The second technical scheme adopted by the invention is as follows:
a compound cortex Phellodendri extract preparation, in the form of liquid, gel or ointment, is prepared from the compound cortex Phellodendri extract prepared by the above preparation method.
Further, a compound phellodendron extract liquid preparation is prepared by adding 0.5g of sodium hydroxy-phenethyl ester into the prepared compound phellodendron extract, adding water to 1000ml, uniformly stirring, standing, refrigerating for 24 hours, filtering, filling and sterilizing.
Further, a compound phellodendron extract gel, adding water into the prepared compound phellodendron extract to 800ml, stirring uniformly, standing, refrigerating for 24 hours, filtering, and reserving filtrate for later use;
dissolving ethylparaben 1g in propylene glycol 50ml, mixing with the filtrate, adding carbomer 10g, stirring to swell, adding 10% triethanolamine, and adjusting pH to 6.0-7.0.
Further, a compound phellodendron extract ointment is prepared by adding 0.5g of ethylparaben, 50g of lanolin and a proper amount of vaseline into the prepared compound phellodendron extract to prepare 1000 g.
The third technical scheme adopted by the invention is as follows:
the compound phellodendron extract prepared by the preparation process is applied to preparing antiallergic drugs.
Further, the antiallergic agent is an antiallergic agent for skin allergy.
The invention has the beneficial effects that:
the invention provides a preparation process of a compound phellodendron extract, the compound phellodendron extract and antiallergic application, aiming at key process parameters influencing the berberine hydrochloride transfer rate, the preparation process comprises the steps of crushing raw phellodendron, and using the crushed phellodendron in combination with poloxamer under the condition of proper solubilizer critical micelle concentration, so that the tolerance of another solubilizer in a thermal environment is improved, the problem of low solubilization efficiency caused by precipitation turbidity or layering of the solubilizer during heating extraction is solved, the content and stability of berberine hydrochloride and other effective components are obviously improved, and meanwhile, paints, gels, ointments and the like prepared by the extract have better transdermal absorption effects; on the premise of improving the transfer rate of effective components and the transdermal absorption effect, the extract is unexpectedly found to show remarkable treatment effect in the related field of antianaphylaxis.
Detailed Description
In order to clearly illustrate the technical features of the present invention, the present invention is explained in detail by the following embodiments.
Example 1
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Decocting the five raw materials with water for three times, wherein the first time is 1 hour, the second time is 45 minutes, and the third time is 30 minutes, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell is obtained, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 2
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing polyoxyethylene hydrogenated castor oil with the mass fraction of 0.1% into the five raw materials, decocting for three times, namely 1 hour for the first time, 45 minutes for the second time and 30 minutes for the third time, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell exists, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing. .
Example 3
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing polyoxyethylene hydrogenated castor oil with the mass fraction of 0.05% and poloxamer with the mass fraction of 0.05% into the five raw materials, decocting for three times, wherein the first time is 1 hour, the second time is 45 minutes, and the third time is 30 minutes, and combining the decoction; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell exists, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 4
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing 1.0 mass percent of span 40 into the five raw materials, decocting for three times, namely 1 hour for the first time, 45 minutes for the second time and 30 minutes for the third time, and combining the decoctions; filtering, concentrating the filtrate to obtain a clear paste with a relative density of 1.10-1.15(50 ℃), adding ethanol until the ethanol content reaches 70%, standing for 24 hours, filtering, concentrating the filtrate under reduced pressure until no ethanol smell exists, adding water to 1000ml, stirring uniformly, standing, refrigerating for 24 hours, filtering, filling, and sterilizing to obtain the traditional Chinese medicine composition.
Example 5
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing span 40 accounting for 0.5 percent of the mass fraction and poloxamer accounting for 0.05 percent into the five raw materials, decocting for three times, wherein the decoction is 1 hour for the first time, 45 minutes for the second time and 30 minutes for the third time, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell is obtained, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 6
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing 1.0 mass percent of Tween 80 into the five raw materials, decocting for three times, namely 1 hour for the first time, 45 minutes for the second time and 30 minutes for the third time, and combining the decoctions; filtering, concentrating the filtrate to obtain a clear paste with a relative density of 1.10-1.15(50 ℃), adding ethanol until the ethanol content reaches 70%, standing for 24 hours, filtering, concentrating the filtrate under reduced pressure until no ethanol smell exists, adding water to 1000ml, stirring uniformly, standing, refrigerating for 24 hours, filtering, filling, and sterilizing to obtain the traditional Chinese medicine composition.
Example 7
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing 0.5% of Tween 80 and 0.05% of poloxamer by mass into the five raw materials, decocting for three times, wherein the first time is 1 hour, the second time is 45 minutes, and the third time is 30 minutes, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell is obtained, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 8
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding poloxamer with the mass fraction of 0.05% into the five raw materials, decocting for three times, namely 1 hour for the first time, 45 minutes for the second time and 30 minutes for the third time, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell exists, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 9
A preparation process of a compound phellodendron extract comprises the following raw materials in a formula: 80g of fructus forsythiae, 40g of golden cypress, 40g of honeysuckle, 40g of dandelion and 2.4g of centipede.
Adding water containing polyoxyethylene hydrogenated castor oil with the mass fraction of 0.05%, tween 80 with the mass fraction of 0.5% and poloxamer with the mass fraction of 0.05% into the five raw materials, decocting for three times, wherein the first time is 1 hour, the second time is 45 minutes, and the third time is 30 minutes, and combining the decoctions; filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.10-1.15(50 deg.C), adding ethanol to make ethanol content reach 70%, standing for 24 hr, filtering, concentrating the filtrate under reduced pressure until no ethanol smell is obtained, adding water to 1000ml, stirring, standing, refrigerating for 24 hr, filtering, bottling, and sterilizing.
Example 10
The same as the preparation process of the compound phellodendron amurense extract in example 9, except that the compound phellodendron amurense extract is decocted by adding water containing 0.5% of span 40, 0.5% of tween 80 and 0.05% of poloxamer by mass.
Example 11
The same as the preparation process of the compound phellodendron amurense extract in example 9, except that the compound phellodendron amurense extract is decocted by adding water containing 0.05% by mass of polyoxyethylene hydrogenated castor oil, 0.5% by mass of span and 0.05% by mass of poloxamer.
Example 12
The same procedure is followed as in example 9 except that the mixture is decocted with water containing 0.05% polyoxyethylene hydrogenated castor oil, 0.5% span 40, 0.5% tween 80 and 0.05% poloxamer.
The results of measuring the transfer rate of the effective components such as berberine hydrochloride in the extracts prepared in the above examples are shown in table 1 below.
The method for measuring the transfer rate of the berberine hydrochloride comprises the following steps: the berberine hydrochloride content in the sample is mg/the berberine hydrochloride content in the phellodendron; the forsythin transfer rate determination method comprises the following steps: the forsythin content mg in the sample/the forsythin content mg in the forsythia; the method for measuring the transfer rate of the chlorogenic acid comprises the following steps: the chlorogenic acid content in the sample is mg/total chlorogenic acid content in the honeysuckle and the dandelion.
TABLE 1
Figure BDA0003193814530000071
Table 1 the results show that: the transfer rates of different active ingredients are improved to different degrees by adding the solubilizer into the decoction water. The effect of improving the berberine hydrochloride transfer rate by independently adding poloxamer is not obvious, but the poloxamer and other single solubilizing agents are added in a pairwise compatibility manner, so that the properties of the extracting solution are improved, and the solubilizing efficiency is improved; in examples 3, 5 and 7, a single solubilizer and poloxamer are used in pairwise combination, so that the transfer rate of active ingredients such as berberine hydrochloride is obviously improved compared with the existing single solubilizer under the condition of ensuring the good properties of no turbid layering of the extraction solution, and the effect of example 7 is optimal. And when the poloxamer and two other complex solubilizers are added in three compatibility or the poloxamer and the other complex solubilizers are added in four compatibility, compared with the combination of the poloxamer and the single solubilizer, the properties of the extracting solution are influenced, and the phenomenon of turbidity or layering occurs, so that the solubilizing effect is interfered. The reason may be that there is an optimal quantitative relationship between the type and the ratio of poloxamer and solubilizer.
Example 13
The process for preparing the compound phellodendron bark extract as in examples 1-12, wherein the difference is that before decocting, phellodendron bark is firstly pulverized into coarse powder, then mixed with the other four raw materials, then water is added for decocting, the relative density of the clear paste obtained by concentrating the filtrate is 1.10-1.15 at 50 ℃, ethanol is added to make the alcohol content reach 70%, the mixture is stood for 24h, filtered and concentrated under reduced pressure until no alcohol smell exists. Adding water, stirring, standing, refrigerating for 24 hr, and filtering.
The results obtained by modifying this example as described above are shown in examples 13-1, 13-2, 13-3, 13-4, 13-5, 13-6, 13-7, 13-8, 13-9, 13-10, 13-11 and 13-12. And (3) measuring the content of berberine hydrochloride of the sample with each result by the following method:
octadecylsilane chemically bonded silica is used as a filler in chromatographic conditions and system applicability tests; acetonitrile-0.033 mol/L potassium dihydrogen phosphate solution (35:65) is used as a mobile phase; the detection wavelength was 347 nm. The theoretical plate number is not less than 3000 calculated according to berberine hydrochloride peak.
Preparation of reference substance solution taking appropriate amount of berberine hydrochloride reference substance, precisely weighing, and adding methanol to obtain solution containing 8 μ g per 1 ml.
Preparation of test solution 3ml of each sample of this example was measured precisely, placed in a 10ml measuring flask, added with 5ml of methanol, placed in a 60 ℃ water bath and kept warm for 15 minutes, taken out, sonicated (power 500W, frequency 40kHz) for 30 minutes, added with methanol to the scale, shaken well, filtered, and the subsequent filtrate was taken. The results are shown in Table 2.
TABLE 2
Figure BDA0003193814530000081
Figure BDA0003193814530000091
As can be seen from table 2, in the embodiment in which the preparation operation is continuously optimized for each of the foregoing embodiments, the phellodendron bark is coarsely crushed in advance, and different solubilizers and compatibility combinations are added, the concentration of berberine hydrochloride in which each pair of solubilizers is compatible with each other by using one of poloxamer, polyoxyethylene hydrogenated castor oil, span, and tween 80 is increased, compared with the group without poloxamer; compared with the group that three kinds of combination compatibility are carried out on two kinds of poloxamer and polyoxyethylene hydrogenated castor oil, span and tween 80, or the group that four kinds of combination compatibility are carried out on three kinds of poloxamer and polyoxyethylene hydrogenated castor oil, span and tween 80, the efficiency of improving the concentration of berberine hydrochloride is optimal in the embodiment 13-7; in examples 3 and 5, compared with the group of compatibility of various solubilizers with poloxamers, the increase of the berberine hydrochloride concentration is reduced, but the product property is still better than that of the group of compatibility of various solubilizers with poloxamers.
Example 14
Application of compound phellodendron extract prepared by the preparation process in preparation of anti-skin allergy medicament
1. Comparative test for antiallergic evaluation
Selecting 5 mice, weighing 20mg/mL ovalbumin physiological saline solution as sensitizing solution, injecting 0.2mL sensitizing solution into the abdominal cavity of each animal for sensitization, 1 time every other day, and 3 times in total, carrying out eyeball blood sampling on the mice at 14d after the first sensitization, placing the collected blood sample at normal temperature for 40min, centrifuging at 3000r/min4 ℃ for 10min, separating serum, and placing in a refrigerator at 4 ℃ for preparing the subsequent antiserum physiological saline diluent.
Another 70 mice were divided into 7 groups at random according to body mass, namely a negative control group, a model group, a positive control group, a low dose group, a high dose group, a low dose group and a high dose group of the compound phellodendron extract prepared in examples 13-7, and 10 mice in each group. Purified water was administered by gavage to the negative control group and the model group, 1g/kg and 2g/kg of aqueous solutions were administered by gavage to the compound phellodendron extract group prepared in examples 13 to 7 and the compound phellodendron extract (paint) group of example 1, respectively, and except for the positive control group, which was administered by intraperitoneal injection at the experimental 12d, the mice of the other groups were administered by gavage at the experimental 1d, each of which was administered by gavage at 0.1mL/10g for 1 time/d, and were administered for 14d continuously. The positive control group was injected with 1.6mg/kg dexamethasone into the abdominal cavity at 12d, and the injection dose was 0.1mL/10g each. The administration was continued for 3 days by injection. During the test period, the food and water were taken freely.
60min after the last gavage, the backs of the mice were prepared conventionally (3 cm. times.3 cm), and in addition to the normal group, the backs of the other test groups were injected intradermally with 0.2mL of an antiserum physiological saline diluent (a mixed preparation of antiserum prepared previously and stored at 4 ℃ C.: 0.9% physiological saline: 1: 5). After 48h, 0.2mL of mixed solution of 1% ovalbumin and normal saline is injected into tail vein for sensitization.
Blood is taken from mouse eyeballs, the collected blood sample is placed at normal temperature for 40min, centrifuged at 3000r/min4 ℃ for 10min, serum is separated, and the levels of immune globulin E (IgE) and leukotriene B4 (LTB4) in the serum are determined according to the kit instructions.
Table 4 below shows the data of the effect of the extract of phellodendron amurense prepared in examples 13-7 on the serum IgE and LTB4 levels in mice of passive skin allergy model
TABLE 4
Group of IgE(ng/ml) LTB4(pg/ml)
Negative control group (NC) 4.1 16.3
Model set (M) 12.6 37.6
Positive control group (AC) 4.6 16.8
Example 13-7 Low dose group of Compound Phellodendri cortex extract (TQW-L) 5.1 22.4
Example 13-7 high dose group of Compound Phellodendri cortex extract (TQW-H) 4.5 16.5
Example 1 Low dose Compound Phellodendri cortex liquid paint (HBY-L) 12.2 37.2
EXAMPLE 1 Compound Phellodendri cortex liquid paint high dose group (HBY-H) 12.3 36.9
As can be seen from the data in Table 4, the compound cortex Phellodendri extracts prepared in examples 13-7 of the present invention can significantly reduce the level of IgE in the serum of sensitized mice, and can effectively control the increase of the level of LTB4 in the serum of sensitized mice, so that the effect of high-dose antiallergic effect is more significant. The existing compound phellodendron amurense liquid liniment, namely the product in the embodiment 1, has no obvious antiallergic effect. This phenomenon may be associated with the same increase in the content and bioavailability of certain antiallergic ingredients as the addition of the solubilizing agent. Compared with the western medicine dexamethasone of the positive control group, the high-dose group in the embodiments 13-7 of the invention has the advantage of anti-allergic effect.
The above-described embodiments should not be construed as limiting the scope of the invention, and any alternative modifications or alterations to the embodiments of the present invention will be apparent to those skilled in the art.
The present invention is not described in detail, but is known to those skilled in the art.

Claims (9)

1. The preparation process of the compound phellodendron extract is characterized in that the compound phellodendron extract is prepared from the following raw materials in parts by weight: 20-120 parts of fructus forsythiae, 20-60 parts of golden cypress, 20-60 parts of honeysuckle, 20-60 parts of dandelion and 1-5 parts of centipede; the extraction preparation method comprises the following operation steps:
taking the phellodendron amurense in parts by weight, and crushing the phellodendron amurense into coarse powder; mixing with other raw materials; adding water containing solubilizer, decocting, filtering, concentrating the filtrate to obtain fluid extract, and extracting with ethanol;
the solubilizer is a compound composition of tween 80, span 40 or polyoxyethylene hydrogenated castor oil and poloxamer;
the content of berberine hydrochloride in the prepared compound cortex Phellodendri extract is not less than 1.0% of dry product.
2. The preparation process of the compound phellodendron amurense extract according to claim 1, wherein the solubilizer is a compound composition of tween 80 and poloxamer; the solubilizer accounts for 0.55 to 1.1 percent of the water for decoction; wherein the dosage ratio of the Tween 80 to the poloxamer is 10: 1.
3. The preparation process of the compound phellodendron amurense extract according to claim 1, wherein the solubilizer is a compound composition of span 40 and poloxamer, and accounts for 0.55-1.1% of the amount of water used for decoction; wherein the dosage ratio of span 40 to poloxamer is 10: 1.
4. The preparation process of the compound phellodendron amurense extract according to claim 1, wherein the solubilizer accounts for 0.1-0.2% of the amount of water used for decoction; wherein the dosage ratio of the polyoxyethylene hydrogenated castor oil to the poloxamer is 1: 1.
5. The process for preparing a compound phellodendron amurense extract according to claim 1, wherein the decoction operation comprises: decocting for 3 times, 1 hr for the first time, 45 min for the second time, and 30 min for the third time, and mixing decoctions.
6. The preparation process of the compound phellodendron amurense extract according to claim 1, wherein the relative density of the clear paste obtained by concentrating the filtrate is 1.10-1.15 at 50 ℃; the alcohol extraction comprises adding ethanol to make the alcohol content reach 70%, standing for 24h, filtering, and concentrating under reduced pressure until no alcohol smell is produced.
7. A compound phellodendron extract preparation, which is characterized in that the liquid preparation, gel or ointment prepared from the compound phellodendron extract prepared by the preparation process of any one of claims 1 to 6.
8. Use of the extract of phellodendron amurense prepared by the process according to any one of claims 1 to 6 for preparing antiallergic agent.
9. Use according to claim 8, wherein the antiallergic agent is an antiallergic agent for skin allergy.
CN202110888781.2A 2021-08-03 2021-08-03 Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application Pending CN113476520A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110888781.2A CN113476520A (en) 2021-08-03 2021-08-03 Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110888781.2A CN113476520A (en) 2021-08-03 2021-08-03 Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application

Publications (1)

Publication Number Publication Date
CN113476520A true CN113476520A (en) 2021-10-08

Family

ID=77945410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110888781.2A Pending CN113476520A (en) 2021-08-03 2021-08-03 Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application

Country Status (1)

Country Link
CN (1) CN113476520A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967184A (en) * 2021-12-15 2022-01-25 山东汉方制药有限公司 Antibacterial and anti-inflammatory compound cortex phellodendri composition, preparation method thereof and cosmetic containing composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106031756A (en) * 2015-03-12 2016-10-19 山东汉方制药有限公司 Compound amur cork-tree temperature-sensitive gel for treating sore and ulcer and traumatic infection and preparing method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106031756A (en) * 2015-03-12 2016-10-19 山东汉方制药有限公司 Compound amur cork-tree temperature-sensitive gel for treating sore and ulcer and traumatic infection and preparing method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
健客网: "复方黄柏液对过敏有效吗?", 《健客网HTTPS://WWW.JIANKE.COM/A/20150327/1433837.HTML》 *
翟文丰等: "超声-表面活性剂法提取黄柏生物碱工艺研究", 《云南中医中药杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967184A (en) * 2021-12-15 2022-01-25 山东汉方制药有限公司 Antibacterial and anti-inflammatory compound cortex phellodendri composition, preparation method thereof and cosmetic containing composition
CN113967184B (en) * 2021-12-15 2023-07-28 山东汉方制药有限公司 Antibacterial and anti-inflammatory compound phellodendron bark composition, preparation method thereof and cosmetic containing same

Similar Documents

Publication Publication Date Title
US4708949A (en) Therapeutic composition from plant extracts
CN102600219B (en) Total flavone extract of abelmoschus manihot and preparing method of total flavone extract
US4795742A (en) Therapeutic composition from plant extracts
CN108888676A (en) A kind of Chinese medicine composition and preparation method thereof for treating eczema
CN113476520A (en) Preparation process of compound cortex phellodendri extract, compound cortex phellodendri extract preparation and antiallergic application
CN110025705A (en) A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis
CN115444893B (en) Uric acid reducing active substance composition and application thereof
CN101744986B (en) Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof
Koo et al. Extraction of hypotensive principles from seeds of Cassia tora
CN100482266C (en) Medical composite prepared by sarcandra and oldenlandia
CN101744991B (en) Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof
CN101745017B (en) Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof
CN101745008B (en) Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof
CN101744993A (en) Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof
CN101744996B (en) Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof
CN110548076A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing eczema
CN109985075B (en) Ginkgo leaf extract injection and preparation method thereof
CN114632127B (en) Traditional Chinese medicine composition and preparation for treating pediatric jaundice as well as preparation method and application of traditional Chinese medicine composition and preparation
CN110237110B (en) Acanthopanax senticosus extract and extraction method and application thereof
CN111529658B (en) Ointment for treating rotavirus enteritis and preparation method thereof
CN114949025B (en) Qianli optical gel for treating diabetic foot and postoperative care of hemorrhoids
CN116920061B (en) Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof
CN1628754A (en) Local externally applied itch stopping garlic paint
CN101744990B (en) Method for individually extracting ginseng, radix ophiopogonis and schisandra chinensis and preparation thereof
CN101744994B (en) Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20211008

RJ01 Rejection of invention patent application after publication